DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

DaVita (NYSE:DVA) highlighted progress in value-based kidney care on March 18, 2026, citing improved quality metrics, shared savings and scale in coordinated care.

Rhea-AI Summary

DaVita (NYSE:DVA) highlighted progress in value-based kidney care on March 18, 2026, citing improved quality metrics, shared savings and scale in coordinated care.

Key points: a 9% Total Quality Score improvement, >$200 million in cumulative shared savings, and management of $5+ billion in medical costs under management, tied to better treatment starts and reduced catheter use.

Positive

• $200M+ cumulative shared savings delivered since program inception
• $5B+ in medical costs under management across value-based arrangements
• Total Quality Score +9% year-over-year improvement
• High Performers contribution: 34% of pool while representing 28% of participants

Negative

• None.

Argus Mar 18 session

-0.77% close to close Open Argus

Details

News Market Reaction – DVA

On Mar 18, the day this news came out, DVA closed 0.77% below the previous close.

Data tracked by StockTitan Argus for the Mar 18 session.

Key Figures

Total Quality Score improvement: 9% Shared savings: More than $200 million High Performers Pool share: 34% +2 more

Total Quality Score improvement

9%

Year-over-year improvement in CKCC Total Quality Score

Shared savings

More than $200 million

Shared savings delivered by DaVita entities since CKCC inception

High Performers Pool share

34%

DaVita’s share of CKCC High Performers Pool

Program participation share

28%

DaVita’s share of CKCC participants

Medical costs under management

More than $5 billion

Medical costs managed under DaVita value-based care arrangements

Historical Context

5 past events · Latest: Feb 24

5 events

1. Feb 24

   Conference participation

   24h Move

   -0.2%

   Announcement of participation in TD Cowen health care conference.

2. Feb 02

   Earnings results

   24h Move

   +21.2%

   Reported Q4 and full-year 2025 revenues, EPS, and cash flow metrics.

3. Feb 02

   Strategic investment

   24h Move

   +1.7%

   Strategic investment in Elara Caring to expand kidney-focused home care.

4. Jan 21

   Earnings call setup

   24h Move

   +2.3%

   Scheduling and access details for the Q4 2025 earnings call.

5. Jan 06

   Board/AI-related news

   24h Move

   +0.7%

   AI-focused company Tolion highlighting DaVita board involvement and growth plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

center for medicare & medicaid innovation (cMMI), comprehensive kidney care contracting (ckcc), central venous catheter (cvc), kidney replacement therapy

4 terms

center for medicare & medicaid innovation (cMMI) regulatory

"scaled programs sponsored by the Center for Medicare & Medicaid Innovation (CMMI)."

A federal agency within the U.S. Medicare and Medicaid system that designs and tests new payment and care models intended to lower costs and improve patient outcomes. For investors, it acts like a policy testing ground: its pilots and rules can reshape how hospitals, insurers, drug makers and medical device companies get paid, which can change revenue and profitability across the healthcare sector.

comprehensive kidney care contracting (ckcc) medical

"results from the Comprehensive Kidney Care Contracting (CKCC) option within CMMI's Kidney Care Choices model."

A Medicare payment and care model that lets provider groups and organizations coordinate services for people with advanced kidney disease while taking shared responsibility for costs and quality; participants can earn bonuses or incur penalties based on how well they control spending and outcomes. For investors, it matters because it shifts revenue and financial risk toward care managers — like hiring a contractor to deliver a whole house rather than paying for each nail — so efficient operators may boost margins while inefficient ones can face losses.

central venous catheter (cvc) medical

"Experience lower rates of central venous catheter (CVC) use, supporting safer treatment initiation."

A central venous catheter (CVC) is a thin, flexible tube inserted into a large vein near the neck, chest or groin to deliver medications, fluids, blood products, or to draw blood and monitor circulation for patients who need ongoing or intensive treatment. Investors care because the device and its related procedures, safety profile, regulatory approvals, and reimbursement drive sales, clinical adoption and hospital spending—think of a CVC as a building’s main water line that enables heavy, continuous supply and monitoring.

kidney replacement therapy medical

"Begin kidney replacement therapy with a planned or optimal start, including increased use of home-based treatment options."

Kidney replacement therapy is medical treatment that takes over the blood-cleaning and fluid-balancing jobs of failed kidneys, most commonly via dialysis machines or by transplanting a donor kidney. Investors watch it because it drives durable demand for devices, drugs, clinics and transplant services, and changes in technology, regulation or reimbursement can materially affect costs, patient access and the revenues of companies in the renal care market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.

DENVER, March 18, 2026 /PRNewswire/ -- DaVita today highlighted continued progress in value-based kidney care, underscoring how sustained investment in coordinated care models is translating into improved outcomes for people living with kidney disease. That progress is evident across both industry partnerships with major insurers and scaled programs sponsored by the Center for Medicare & Medicaid Innovation (CMMI).

For more than two decades, DaVita has invested in care innovation to address the complex, fragmented experience faced by people living with kidney disease. Value-based models enable whole-person, longitudinal care rather than episodic treatment.

CKCC Results Show Momentum as the Model Matures

DaVita's progress is reflected in results from the Comprehensive Kidney Care Contracting (CKCC) option within CMMI's Kidney Care Choices model. As the largest ongoing federal value-based kidney care demonstration, CKCC enables providers and physicians to test and refine coordinated care approaches at scale.

Recently published performance results through 2024 show continued year-over-year improvements as the model matures.

• Stronger quality outcomes: DaVita achieved a 9% improvement in its Total Quality Score, driven by gains in optimal treatment starts, patient activation and behavioral health support.
• Greater shared savings: DaVita entities have delivered more than $200 million in shared savings since the program's inception.
• High Performers recognition: DaVita and its physician partners drove an outsized impact, accounting for 34% of the program's High Performers Pool while representing just 28% of participants.

Beyond program metrics alone, these improvements are associated with meaningful downstream effects on clinical quality and long-term population health.

Patients with access to CKCC and related value-based care programs are more likely to:

• Begin kidney replacement therapy with a planned or optimal start, including increased use of home-based treatment options.
• Experience lower rates of central venous catheter (CVC) use, supporting safer treatment initiation.
• Have fewer missed treatments, reflecting stronger engagement and care coordination.

"People living with kidney disease often manage multiple chronic conditions, and strong outcomes depend on close collaboration across the care team," said Dr. Jeff Giullian, chief medical officer for DaVita. "Through value-based models like CKCC, DaVita works alongside partner physicians and care teams to better coordinate care beyond kidney disease and across settings. That shared approach supports earlier intervention, more prepared treatment starts, and better-informed decisions about dialysis, transplantation and care at home."

A Significant and Growing Commitment to Value-Based Care

DaVita has been engaged in value-based care arrangements for more than two decades and now manages more than $5 billion in medical costs under management. Across these models, value-based kidney care is linked to higher transplant rates and greater patient understanding of their condition, enabling more informed, proactive health decisions.

"Value-based kidney care is showing what's possible when providers are given the time and stability to invest in coordinated care," said Misha Palecek, chief transformation officer for DaVita. "We're seeing better-prepared patients, improved experiences and encouraging economics. The lessons emerging from kidney care can help inform how other complex, chronic conditions are managed across the healthcare system — if we stay the course."

Supporting Long-Term Innovation in Kidney Care

DaVita is encouraged that its integrated kidney care programs are demonstrating early signs of financial sustainability alongside improved outcomes. These results reinforce that continued focus on kidney care can drive meaningful gains in healthcare innovation more broadly, with coordinated, accountable care models offering a blueprint for transformation across the healthcare system.

To learn more about DaVita's approach to value-based kidney care, visit DaVita.com/IKC.

About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 25 years. DaVita cares for patients at every stage and setting along their kidney health journey— from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in dialysis centers, in the hospital and in skilled nursing facilities. As of December 31, 2025, DaVita served approximately 295,000 patients at 3,242 outpatient dialysis centers, of which 2,657 centers were located in the United States and 585 centers were located in 14 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties. These forward-looking statements are based on management's current expectations. Various important factors could cause actual results to differ materially from these forward-looking statements, including the risks identified in our U.S. Securities and Exchange Commission filings. DaVita disclaims any obligation to update any forward-looking statement contained in this press release, except as may be otherwise required by law.

Media Contact:
DaVita Newsroom
newsroom@davita.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-highlights-continued-progress-in-value-based-kidney-care-as-ckcc-results-show-year-over-year-improvement-302717802.html

SOURCE DaVita

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What CKCC results did DaVita report on March 18, 2026 for DVA?

DaVita reported a 9% improvement in Total Quality Score year-over-year and more than $200M in shared savings. According to the company, these CKCC results through 2024 show maturing value-based model performance and downstream clinical improvements.

How much in shared savings has DaVita achieved under CKCC and related programs (DVA)?

DaVita entities have delivered more than $200 million in shared savings since program inception. According to the company, this cumulative figure reflects shared financial returns from coordinated care in the CKCC demonstration.

What operational scale does DaVita claim in value-based kidney care (DVA)?

DaVita manages over $5 billion in medical costs under management across value-based arrangements. According to the company, that scale supports investment in longitudinal care and coordination across providers and settings.

What patient outcomes improved under DaVita's CKCC participation (DVA)?

Patients showed more planned or optimal dialysis starts, greater home-treatment use, fewer missed treatments, and lower CVC rates. According to the company, these outcomes reflect stronger engagement and care coordination in CKCC.

What does DaVita say about High Performers in the CKCC program (DVA)?

DaVita and physician partners accounted for 34% of the High Performers Pool while representing 28% of participants. According to the company, this indicates outsized program impact from its teams within the demonstration.